Home Tags AML

Tag: AML

Woman Having Chemotherapy With Nurse Using Digital Tablet

Institutional Review Board Approves Phase I Trial with GTB-3550

The University of Minnesota's Institutional Review Board (IRB) and Cancer Protocol Review Committee (CPRC) has granted GT Biopharma (Westlake Village, CA 91362), permission to...

Merus Therpeutics: Seeking to Advance Immuno-Oncology

In Oncology, many new developments of the last decade have made it possible to treat cancers in ways that are better-targeted, more potent, and...

Independent Data Monitoring Committee Recommends Pivotal Phase III SIERRA Trial Continue...

Independent Data Monitoring Committee (DMC) for the Pivotal Phase III SIERRA Trial (Study of Iomab-B for Elderly Relapsed or Refractory AML) of Iomab-B (131I...

IMGN779 Demonstrates Favorable Safety Profile with repeat Dosing and no Dose-limiting...

The first-in-human data demonstrate the safety and tolerability of IMGN779, being developed by ImmunoGen, across seven dose levels, with no dose limiting toxicities (DLTs),...

Pfizer Resubmits Application for Gemtuzumab Ozogamicin to European and American Regulators

In late January 2017 Pfizer's Biologics License Application (BLA) for gemtuzumab ozogamicin (Mylotarg®; previously known as CMA-676) was accepted for filing by the U.S....

Clinical Hold on Several Phase I Trials of Vadastuximab Talirine; Enrollment...

Earlier today Seattle Genetics, an innovative biotechnology company that develops and commercializes novel antibody-based therapies for the treatment of cancer, confirmed that it has...

Phase I Trial of SGN-CD123A for Patients with Relapsed or Refractory...

Seattle Genetics confirmed enrollment of the first patient in a multicenter phase I clinical trial of SGN-CD123A for patients with relapsed or refractory (r/r)...

Vadastuximab Talirine (SGN-CD33A) Combination Therapy Evaluates Safety and Activity for Patients...

A new phase I/II clinical trial of vadastuximab talirine, also known as SGN-CD33A; 33A (Seattle Genetics), in combination with azacitidine (Vidaza®; Celgene Corporation) in patients with...

Study Links Gemtuzumab Ozogamicin Response in Pediatric AML to Expression Level...

Expression CD33 is largely restricted to hematopoietic cells. Because CD33 is consistently expressed on acute myeloid leukemia or AML blasts, it makes a promising...

IMGN779 Induces DNA Damage, Cell Cycle Arrest, and Apoptosis in AML...

CD33 is broadly expressed on leukemic blasts of patients with acute myeloid leukemia.  Although nearly 80% of patients show a high initial response rates to chemotherapy, many...

DOWNLOAD